Drug
Daplusiran Tomligisiran Dose Level 1
Daplusiran Tomligisiran Dose Level 1: highest development phase Phase 2, developed by GlaxoSmithKline. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- GlaxoSmithKline
Trials
| Drug | Phase | Indication |
|---|---|---|
| Daplusiran/Tomligisiran Dose Level 1 NCT06537414 | Phase 2 | Chronic Hepatitis B Virus Infection |
Latest
No recent events.
Follow Daplusiran Tomligisiran Dose Level 1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.